Literature DB >> 24306023

Transmission of vaccinia virus, possibly through sexual contact, to a woman at high risk for adverse complications.

Maria A Said1, Charles Haile, Venkataraman Palabindala, Naomi Barker, Robert Myers, Ruth Thompson, Lucy Wilson, Frances Allan-Martinez, Jay Montgomery, Benjamin Monroe, Danielle Tack, Mary Reynolds, Inger Damon, David Blythe.   

Abstract

Severe adverse events, including eczema vaccinatum (EV), can result after smallpox vaccination. Persons at risk for EV include those with underlying dermatologic conditions, such as atopic dermatitis. We investigated a case of vaccinia infection, possibly acquired during sexual contact with a recently vaccinated military service member, in a female Maryland resident with atopic dermatitis. The U.S. Department of Defense's Vaccine Healthcare Centers Network (VHCN) and the Centers for Disease Control and Prevention (CDC) worked in conjunction with the patient's physician and the Maryland Department of Health and Mental Hygiene (DHMH) to confirm the diagnosis, ensure treatment, and prevent further transmission. Specimens collected from the patient were tested at the DHMH laboratories and were positive by real-time polymerase chain reaction for nonvariola orthopoxvirus. Testing at the CDC verified the presence of vaccinia-specific DNA signatures. Continuing spread of the patient's lesions led to the administration of vaccinia immune globulin and strict infection control measures to prevent tertiary transmission to vulnerable family members, also with atopic dermatitis. VHCN contacted the service member to reinforce vaccination site care and hygiene. This case underscores the importance of prevaccination education for those receiving the smallpox vaccine to protect contacts at risk for developing severe adverse reactions. Reprint &
Copyright © 2013 Association of Military Surgeons of the U.S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24306023     DOI: 10.7205/MILMED-D-13-00233

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  5 in total

1.  The new face of monkeypox virus: an emerging global emergency.

Authors:  Nityanand Jain; Edouard Lansiaux; Raimonds Simanis
Journal:  New Microbes New Infect       Date:  2022-05-27

2.  Poor Antigen Processing of Poxvirus Particles Limits CD4+ T Cell Recognition and Impacts Immunogenicity of the Inactivated Vaccine.

Authors:  Katherine S Forsyth; Brian DeHaven; Mark Mendonca; Sinu Paul; Alessandro Sette; Laurence C Eisenlohr
Journal:  J Immunol       Date:  2019-01-30       Impact factor: 5.422

3.  Monkeypox in 2022: A new threat in developing.

Authors:  Mansoor Ahmed; Haseena Naseer; Mateen Arshad; Afnan Ahmad
Journal:  Ann Med Surg (Lond)       Date:  2022-06-07

4.  Crowdsourced Identification of Possible Allergy-Associated Factors: Automated Hypothesis Generation and Validation Using Crowdsourcing Services.

Authors:  Eiji Aramaki; Shuko Shikata; Satsuki Ayaya; Shin-Ichiro Kumagaya
Journal:  JMIR Res Protoc       Date:  2017-05-16

Review 5.  The infectious complications of atopic dermatitis.

Authors:  Vivian Wang; Juri Boguniewicz; Mark Boguniewicz; Peck Y Ong
Journal:  Ann Allergy Asthma Immunol       Date:  2020-08-07       Impact factor: 6.347

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.